Vanguard Global ex-US Real Estate ETF
Analysts’ Recommendations for Arrowhead and Its Peers
Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them.
Highlights of Bridgewater Associates’ New Positions in 4Q14
Ray Dalio’s Bridgewater Associates filed its fourth-quarter 13F in February 2015. In 4Q14, the fund had opened four new positions.